Apex Capital Management’s Charles River Laboratories CRL Stock Holding History

Apex Capital Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$21.4M	Buy	281,742 +45,622	+19%	+$3.38M	0.47%	72
2015 Q4	$19M	Buy	236,120 +18,222	+8%	+$1.31M	0.42%	75
2015 Q3	$13.8M	Sell	217,898 -48,969	-18%	-$3.52M	0.31%	82
2015 Q2	$18.8M	Buy	266,867 +54,027	+25%	+$4M	0.4%	75
2015 Q1	$16.9M	Buy	212,840 +31,547	+17%	+$2.33M	0.4%	72
2014 Q4	$11.5M	Buy	181,293 +45,373	+33%	+$2.84M	0.31%	77
2014 Q3	$8.12M	Buy	135,920 +13,264	+11%	+$759K	0.24%	82
2014 Q2	$6.57M	Buy	122,656 +16,866	+16%	+$925K	0.2%	93
2014 Q1	$6.38M	Buy	105,790 +14,329	+16%	+$835K	0.23%	89
2013 Q4	$4.85M	Sell	91,461 -442	-0.5%	-$22.2K	0.18%	97
2013 Q3	$4.25M	Buy	91,903 +14,627	+19%	+$671K	0.19%	96
2013 Q2	$3.17M	Buy	+77,276	New	+$3.31M	0.15%	116

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Apex Capital Management's CRL Position: Q1 2016 in Review

Apex Capital Management increased its Charles River Laboratories (CRL) stake by 19% in Q1 2016, buying an estimated $3.38M and bringing the position to 281,742 shares worth $21.4M. The position accounts for 0.47% of the portfolio, ranked #72.

Apex Capital Management first reported a position in CRL in Q2 2013 and has held it in 12 quarters since. 264 funds tracked by Wall St. Rank hold CRL as of Q1 2016.

Apex Capital Management held 281,742 shares of Charles River Laboratories worth $21.4M as of Q1 2016.
Apex Capital Management bought 45,622 Charles River Laboratories shares in Q1 2016, an estimated $3.38M.
Charles River Laboratories made up 0.47% of Apex Capital Management's portfolio in Q1 2016, its #72 holding.
Apex Capital Management first reported a position in Charles River Laboratories in Q2 2013 and has held it in 12 quarters since.
264 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2016.

Based on Apex Capital Management's 13F filing for Q1 2016, filed 27 Apr 2016.